Navidea Biopharmaceuticals Inc RSI
Was ist das RSI von Navidea Biopharmaceuticals Inc?
RSI von Navidea Biopharmaceuticals Inc ist 48.70
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Navidea Biopharmaceuticals Inc
Was macht Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Unternehmen mit rsi ähnlich Navidea Biopharmaceuticals Inc
- Autozone hat RSI von 48.69
- iShares Silver Trust hat RSI von 48.69
- Hannan Metals hat RSI von 48.69
- MediPharm Labs hat RSI von 48.69
- Red Rock Resources plc hat RSI von 48.69
- Hypoport AG hat RSI von 48.69
- Navidea Biopharmaceuticals Inc hat RSI von 48.70
- Best of the Best PLC hat RSI von 48.71
- Evergold hat RSI von 48.71
- Mitesco hat RSI von 48.71
- Chambal Fertilisers and Chemicals hat RSI von 48.71
- First Bancorp Inc (ME) hat RSI von 48.71
- China Public Procurement hat RSI von 48.71